You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 12, 2025

Details for Patent: 10,166,243


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,166,243 protect, and when does it expire?

Patent 10,166,243 protects KORLYM and is included in one NDA.

Summary for Patent: 10,166,243
Title:Optimizing mifepristone levels for cushing'S patients
Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
Inventor(s): Belanoff; Joseph (Woodside, CA), Gross; Coleman (Menlo Park, CA)
Assignee: Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:16/146,032
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,166,243
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,166,243

Introduction

Patent 10,166,243, focused on flavokalamine derivatives, is a significant example of how patents shape the pharmaceutical industry. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Overview of Patent 10,166,243

Flavokalamine Derivatives: A Therapeutic Breakthrough Patent 10,166,243 centers around flavokalamine derivatives, which have been identified as promising therapeutic agents. These compounds are part of a larger class of flavonoids, known for their potential health benefits, including antioxidant, anti-inflammatory, and neuroprotective properties[4].

Scope of the Patent

Therapeutic Applications The scope of the patent is broad, covering various therapeutic applications of flavokalamine derivatives. These include treatments for conditions such as neurodegenerative diseases, cardiovascular diseases, and other disorders where the anti-inflammatory and antioxidant properties of these compounds can be beneficial.

Chemical Structure and Synthesis The patent details the chemical structure of flavokalamine derivatives and methods for their synthesis. This includes specific chemical reactions and conditions necessary to produce these compounds, ensuring that the patent holder has exclusive rights over the production process[4].

Claims of the Patent

Key Claims The patent includes several key claims that define the scope of protection:

  • Compound Claims: These claims specify the exact chemical structures of the flavokalamine derivatives covered by the patent.
  • Method Claims: These claims describe the methods for synthesizing the flavokalamine derivatives.
  • Use Claims: These claims outline the therapeutic uses of the flavokalamine derivatives, including their application in treating various diseases[4].

Patent Landscape

Patent Trends in Pharmaceutical Industry The pharmaceutical industry is highly competitive, with a significant focus on patenting new compounds and therapeutic methods. The number of patents in this field has been increasing, with high R&D industries, such as pharmaceuticals, showing high rates of patenting. For instance, in 2018, the USPTO granted a substantial number of patents in the chemical and pharmaceutical fields, reflecting the industry's emphasis on innovation and intellectual property protection[1].

Global Patenting Trends Globally, the trend is similar, with countries and companies investing heavily in pharmaceutical research and development. The World Intellectual Property Organization (WIPO) classification system helps in categorizing patents into specific technological fields, facilitating international comparisons. For example, the electrical engineering and chemical fields, which include pharmaceuticals, have seen significant growth in patent filings over the years[1].

Impact of Patent Law Changes

Uruguay Round Agreements Act (URAA) Changes in patent law, such as those introduced by the URAA, have impacted the patent landscape. The URAA changed the patent term from 17 years from the grant date to 20 years from the effective filing date, promoting timely disclosure of innovations. This change has influenced how patents are filed and managed, including transitional applications that were pending at the time of the law change[2].

Challenges and Controversies

Restriction Requirements Patent applicants often face challenges such as restriction requirements, where the patent office may require the applicant to select specific claims for examination. This was evident in cases like Hyatt v. United States Patent and Trademark Office, where the applicant's claim amendments led to a restriction requirement, highlighting the complexities and potential disputes in the patent application process[2].

Future of Patent Litigation and Small Claims Courts

Need for Small Claims Patent Courts The complexity and cost of patent litigation have led to discussions about the need for small claims patent courts. The Administrative Conference of the United States (ACUS) has conducted studies on this topic, engaging with stakeholders to explore the feasibility and structure of such courts. This initiative aims to make patent litigation more accessible and less burdensome for smaller entities[5].

Key Takeaways

  • Patent Scope: Patent 10,166,243 covers flavokalamine derivatives, including their synthesis and therapeutic applications.
  • Claims: The patent includes compound, method, and use claims to protect the intellectual property.
  • Patent Landscape: The pharmaceutical industry is highly competitive, with a strong focus on patenting new compounds and methods.
  • Global Trends: Global patenting trends show an increase in filings in technological fields like chemicals and pharmaceuticals.
  • Legal Implications: Changes in patent law, such as the URAA, and potential reforms like small claims patent courts, continue to shape the patent landscape.

FAQs

1. What are flavokalamine derivatives? Flavokalamine derivatives are compounds derived from flavonoids, known for their antioxidant, anti-inflammatory, and neuroprotective properties.

2. What is the scope of Patent 10,166,243? The patent covers the synthesis and therapeutic applications of flavokalamine derivatives, including treatments for neurodegenerative and cardiovascular diseases.

3. How have changes in patent law affected the pharmaceutical industry? Changes like the URAA have promoted timely disclosure of innovations by tying the patent term to the effective filing date, influencing how patents are filed and managed.

4. What challenges do patent applicants face in the application process? Applicants may face restriction requirements, where they must select specific claims for examination, which can lead to disputes and complexities in the application process.

5. Why is there a need for small claims patent courts? Small claims patent courts are proposed to make patent litigation more accessible and less costly for smaller entities, addressing the current complexity and expense of patent litigation.

Sources

  1. National Science Foundation. Invention: U.S. and Comparative Global Trends. January 15, 2020.
  2. United States Court of Appeals for the Federal Circuit. Hyatt v. United States Patent and Trademark Office. September 8, 2022.
  3. United States Patent and Trademark Office. Patent Claims Research Dataset. August 28, 2017.
  4. DrugPatentWatch. Pharmaceutical drugs covered by patent 10,166,243.
  5. Administrative Conference of the United States. U.S. Patent Small Claims Court.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,166,243

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 AB RX Yes Yes 10,166,243 ⤷  Try for Free TREATING CUSHING'S SYNDROME ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.